Spain
Orikine Bio is a promising entrant in the Biotechnology sector, founded in 2022 and headquartered in Spain. The company emphasizes advancements in engineered cytokines, which are instrumental in treating immune-mediated diseases. With a mission to revolutionize medical therapies, Orikine Bio's approach aims to deliver transformative health solutions, indicating strong potential for significant impact in patient care.
In its recent Seed Round concluded on 18 July 2023, the company secured a substantial funding of €5.50M, showcasing early confidence from well-regarded investors such as Asabys Partners and AdBio partners. This financial backing highlights the credible interest and belief in the start-up’s innovation and possible market disruption capabilities.
Overall, Orikine Bio represents an impactful opportunity within the immune-treatment space, backed by investors with significant experience in nurturing biotech breakthroughs. The company's promising technology and strategic investor support position it favorably for potential growth and development in the coming years.
